Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL17802313 | 0.98 | GAA (0.48) | GAASMN1; SMN2KMT2ACTBP2TDP1 | |
| SCHEMBL1399175 | 0.81 | SMN1; SMN2 (0.56) | GAASMN1; SMN2KMT2ACTBP2TDP1 | |
| SCHEMBL27275466 | 0.80 | CA2 (0.43) | GAALMNAHTTCA12CA1 | |
| SCHEMBL13727493 | 0.80 | CA2 (0.58) | KMT2ACTBP2RAB9ALMNACA2 | |
| SCHEMBL21143491 | 0.79 | FFAR1 (0.51) | GAAPOLBALDH1A1RAB9ALMNA | |
| SCHEMBL17802304 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2KMT2ATDP1ALDH1A1RAB9A | |
| SCHEMBL11982003 | 0.78 | CA2 (0.35) | GAAKMT2AALDH1A1LMNAHTT | |
| SCHEMBL9065640 | 0.78 | CTBP2 (0.48) | GAASMN1; SMN2KMT2ACTBP2TDP1 | |
| SCHEMBL560200 | 0.78 | TPMT (0.38) | CA1CA2 | |
| SCHEMBL11519547 | 0.78 | NPC1 (0.48) | SMN1; SMN2KMT2ACTBP2TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100338074-C | Heterocyclic compounds and cerebral function improvers containing same as active | ZENYAKU KOGYO KK (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1601678-A2 | FUSED PYRROLE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050014754-A1 | Fused pyrrole compounds | SYNTA PHARMACEUTICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| WO-2004082606-A2 | FUSED PYRROLE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2004-09-30 | — | — | WO | disclosed |
| CN-1531540-A | Heterocyclic compounds and cerebral function improvers containing same as active | ������ҩ��ҵ��ʽ���� | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014754-A1 | Fused pyrrole compounds | PDE4A, PDE4B, IL4 | GAA 2038/4885SMN1; SMN2 2813/4885KMT2A 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.